These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 33925625)

  • 1. iPSCs: A Preclinical Drug Research Tool for Neurological Disorders.
    Bonaventura G; Iemmolo R; Attaguile GA; La Cognata V; Pistone BS; Raudino G; D'Agata V; Cantarella G; Barcellona ML; Cavallaro S
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
    Liu Y; Deng W
    Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in Patient-Specific Induced Pluripotent Stem Cells Shed Light on Drug Discovery for Amyotrophic Lateral Sclerosis.
    Lee JH; Liu JW; Lin SZ; Harn HJ; Chiou TW
    Cell Transplant; 2018 Sep; 27(9):1301-1312. PubMed ID: 30033758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neural stem cell-based treatment for neurodegenerative diseases.
    Kim SU; Lee HJ; Kim YB
    Neuropathology; 2013 Oct; 33(5):491-504. PubMed ID: 23384285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Pluripotent Stem Cells in Neurodegenerative Diseases: Potentials, Advances and Limitations.
    Kolagar TA; Farzaneh M; Nikkar N; Khoshnam SE
    Curr Stem Cell Res Ther; 2020; 15(2):102-110. PubMed ID: 31441732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induced Pluripotent Stem Cell (iPSC)-Based Neurodegenerative Disease Models for Phenotype Recapitulation and Drug Screening.
    Chang CY; Ting HC; Liu CA; Su HL; Chiou TW; Lin SZ; Harn HJ; Ho TJ
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32344649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induced pluripotent stem cells-based disease modeling, drug screening, clinical trials, and reverse translational research for amyotrophic lateral sclerosis.
    Okano H; Morimoto S; Kato C; Nakahara J; Takahashi S
    J Neurochem; 2023 Dec; 167(5):603-614. PubMed ID: 37952981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introduction for Stem Cell-Based Therapy for Neurodegenerative Diseases.
    Han F; Lu P
    Adv Exp Med Biol; 2020; 1266():1-8. PubMed ID: 33105491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential therapeutic applications of differentiated induced pluripotent stem cells (iPSCs) in the treatment of neurodegenerative diseases.
    Gao A; Peng Y; Deng Y; Qing H
    Neuroscience; 2013 Jan; 228():47-59. PubMed ID: 23069758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders.
    Okano H; Morimoto S
    Cell Stem Cell; 2022 Feb; 29(2):189-208. PubMed ID: 35120619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of human adipose-derived stem cells in neurological disorders.
    Chang KA; Lee JH; Suh YH
    J Pharmacol Sci; 2014; 126(4):293-301. PubMed ID: 25409785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induced Pluripotent Stem Cells and Their Applications in Amyotrophic Lateral Sclerosis.
    Du H; Huo Z; Chen Y; Zhao Z; Meng F; Wang X; Liu S; Zhang H; Zhou F; Liu J; Zhang L; Zhou S; Guan Y; Wang X
    Cells; 2023 Mar; 12(6):. PubMed ID: 36980310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of Parkinson's disease pathophysiology for the development of cell replacement strategies and drug discovery in neurodegenerative diseases.
    Pan-Montojo F; Funk RH
    CNS Neurol Disord Drug Targets; 2012 Nov; 11(7):907-20. PubMed ID: 23131153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stem Cell Technology for (Epi)genetic Brain Disorders.
    Riemens RJM; Soares ES; Esteller M; Delgado-Morales R
    Adv Exp Med Biol; 2017; 978():443-475. PubMed ID: 28523560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mini-Review: Induced pluripotent stem cells and the search for new cell-specific ALS therapeutic targets.
    Ferraiuolo L; Maragakis NJ
    Neurosci Lett; 2021 Jun; 755():135911. PubMed ID: 33892003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stem cell challenges in the treatment of neurodegenerative disease.
    Feng Z; Gao F
    CNS Neurosci Ther; 2012 Feb; 18(2):142-8. PubMed ID: 22070610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stem cell therapies for neurological disorders: current progress, challenges, and future perspectives.
    Rahimi Darehbagh R; Seyedoshohadaei SA; Ramezani R; Rezaei N
    Eur J Med Res; 2024 Jul; 29(1):386. PubMed ID: 39054501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ropinirole, a New ALS Drug Candidate Developed Using iPSCs.
    Okano H; Yasuda D; Fujimori K; Morimoto S; Takahashi S
    Trends Pharmacol Sci; 2020 Feb; 41(2):99-109. PubMed ID: 31926602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induced pluripotent stem cells in modeling and cell-based therapy of amyotrophic lateral sclerosis.
    Csobonyeiova M; Polak S; Nicodemou A; Danisovic L
    J Physiol Pharmacol; 2017 Oct; 68(5):649-657. PubMed ID: 29375039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induced pluripotent stem cells for neural drug discovery.
    Farkhondeh A; Li R; Gorshkov K; Chen KG; Might M; Rodems S; Lo DC; Zheng W
    Drug Discov Today; 2019 Apr; 24(4):992-999. PubMed ID: 30664937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.